Pneumococcal conjugate vaccination has proved highly effective in eliminating vaccine-type pneumococcal carriage and disease. However, the potential adverse effects of serotype replacement remain a major concern when implementing routine childhood pneumococcal conjugate vaccination programmes. Applying a concise predictive model, we present a ready-to-use quantitative tool to investigate the implications of serotype replacement on the net effectiveness of vaccination against invasive pneumococcal disease (IPD) and to guide in the selection of optimal vaccine serotype compositions. We utilise pre-vaccination data on pneumococcal carriage and IPD and assume partial or complete elimination of vaccine-type carriage, its replacement by non-vaccine-type carriage, and stable case-to-carrier ratios (probability of IPD per carriage episode). The model predicts that the post-vaccination IPD incidences in Finland for currently available vaccine serotype compositions can eventually decrease among the target age group of children
Notes
Cites: Lancet. 2011 Dec 3;378(9807):1962-7321492929
Cites: PLoS One. 2012;7(6):e3973022761879
Cites: PLoS One. 2013;8(2):e5607923457504
Cites: Nat Genet. 2013 Jun;45(6):656-6323644493
Cites: PLoS Med. 2013;10(9):e100151724086113
Cites: J R Soc Interface. 2013 Dec 6;10(89):2013078624132203
Cites: Am J Epidemiol. 2013 Nov 1;178(9):1488-9524013204
Cites: J Infect Dis. 2001 Aug 15;184(4):451-911471103